Table 3.
Definitive concurrentchemoradiotherapy combined with other therapies for unresectable esophageal squamous cell carcinoma: ongoing trials.
| Registration | Phase | Participants | Population | Study Cohort | Control Cohort | Combination therapy | Primary Endpoints | Secondary Endpoints |
|---|---|---|---|---|---|---|---|---|
| NCT04481100 | II | 38 | T3-4N0M0, T1-4N+M0, stage II-IVA ESCC(AJCC 8th) | Itraconazole + Chemotherapy (NP) + Radiotherapy(NP) | Antifungal drug | ORR | LRFS, OS, AEs | |
| NCT04391049 | I | 16 | Unresectable GEJC/ESCC/EAC | OBP-301 + Chemotherapy (Carboplatin + Paclitaxel) + Radiotherapy(NP) | Oncolytic virus | Dose Limiting Toxicity | AEs, CCR, PFS, OS | |
|
NCT05512520 EC-CRT-003 |
II | 126 | Stage IVB ESCC(UICC 8th) | anti-PD1 + Chemotherapy (Fluoropyrimidine or Taxane-based platinum doublet chemotherapy) + Radiotherapy(40-50.4Gy/25-28F) | Chemotherapy (Fluoropyrimidine or Taxane-based platinum doublet chemotherapy) + Radiotherapy(40-50.4GY/25-28F) | Chemotherapy | PFS | OS, ORR, AEs |
|
NCT02409186 NXCEL1311 |
III | 200 | Stage II-III cervical esophageal cancer, Unresectable esophageal cancer (AJCC 7th) | Nimotuzumab + Chemotherapy (Paclitaxel + Cisplatin) + Radiotherapy(59.4Gy/33F) | Placebo + Chemotherapy (Paclitaxel + Cisplatin) + Radiotherapy(59.4GY/33F) | Targeted Therapy | OS |
T, Tumor; N, regional lymph node; M, Metastasis; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; GEJC, gastroesophageal junction cancer; AJCC, American Joint Committee on Cancer; UICC, Union for International Cancer Control; F, fraction; NR, not reported; ORR, objective response rate; LRFS, locoregional recurrence free survival; OS, overall survival; AEs, adverse events; CCR, clinical complete response; PFS, progression-free survival.